Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 5—May 2004

Research

Multidrug-resistant Tuberculosis in Central Asia

Helen Suzanne Cox*Comments to Author , Juan Daniel Orozco*, Roy Male*, Sabine Ruesch-Gerdes†, Dennis Falzon*, Ian Small*, Darebay Doshetov‡, Yared Kebede§, and Mohammed Aziz¶
Author affiliations: *Médecins Sans Frontières Aral Sea Area Programme, Uzbekistan and Turkmenistan, Tashkent, Uzbekistan; †National Reference Centre for Mycobacteria, Borstel, Germany; ‡Ministry of Health, Nukus, Karakalpakstan, Uzbekistan; §Médecins Sans Frontières, Amsterdam, the Netherlands; ¶World Health Organization, Geneva, Switzerland

Main Article

Table 4

Second-line drug resistance resultsa

New Retreatment MDR-TBb
Total Resistant (%) Total Resistant (%) Total Resistant (%)
Karakalpakstan (Uzbekistan)
Prothionamide 106 7 (7) 107 11 (10) 57 9 (16)
Capreomycin 88 1 (1) 101 1 (1) 56 1 (2)
Ofloxacin 88 2 (2) 101 4 (4) 56 1 (2)
Dashoguz (Turkmenistan)
Prothionamide 105 1 (1) 98 4 (4) 22 2 (9)
Capreomycin 89 0 93 0 21 0
Ofloxacin 89 0 93 0 21 0

aAll strains were tested for prothionamide; a representative subset of these were tested for both capreomycin and ofloxacin.
bMDR-TB, multidrug-resistant tuberculosis.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO